EncorePharma began to emerge more than a decade ago at Loma Linda University (LLU), when a previously close-knit group of researchers reunited for an “Encore” performance in their professional lives. Following the company’s 1997 incorporation, EncorePharma’s scientist initially focused on the development of E-7869* ( a potential anti-cancer and anti-Alzheimer’s drug) and on the pharmacology of γ – tocopherol* (part of the Vitamin E complex) and its derivative LLU-α* After two years of active clinical development, EncorePharma licensed  E-7869 (now MPC-7869 also known as FLURIZAN™) to Myriad Genetics for final clinical development and marketing.

*Patent-protected compounds or uses

For more in-depth information, please click here